Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

8 of 35 (80%) irinotecan patients completed 2 cycles (p=0.099) 2. Number of patients receiving full 8 cycles 14 of 41 (34%) HyCAMP(TM) patients compared to 5 of 35 (14%) irinotecan patients completed 8 cycles (p=0.064) 3. Median number of cycles delivered Patients on HyCAMP(TM) received a median of 6 cycles of therapy compared to 2 for irinotecan alone (p=0.005). 4. Disease control rate (Complete Response + Partial Response + Stable Disease) The proportion of patients exhibiting disease control was at least 40% higher in the HyCAMP(TM) arm than the control (analysis partially complete) 5. Median progression free survival Mean progression free survival was 5.2 months for HyCAMP(TM) vs 2.4 months for the control arm (p=0.014).

Please refer to graph available via announcement on the Australian stock exchange (ASX).

    6. Median overall survival

       To be determined


    7. 50% or greater decline in CEA levels

       To be determined


    8. Time to treatment failure

       To be determined


    Principal Investigator

    Assoc. Prof Peter Gibbs, Royal Melbourne Hospital and Western Hospital

CONTACT: Dr. Tracie Ramsdale, Chief Executive Officer, Alchemia Limited,+61-7-3340-0200; Ms Anna Whybird, Phillips Group, +61-7-3230-5000, forAlchemia Limited

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

Post Your Comments:
(Date:12/1/2009)... , ATLANTA, Dec. 1 C...edical device and cardiovascular tissue processing... for 2010. ,, The Company expects total revenue...illion and $123.0 million, which includes between ...eceived from the Department of Defense in connecti...
(Date:12/1/2009)... , PISCATAWAY, N.J., Dec. 1 ...ens.com/hearing) a leading global manufacturer of ...rtnership with Quota International,s Sound Beginni...h September 2010. ,, As part of the renewed par...ide vouchers for 100 free hearing instruments to b...
(Date:12/1/2009)... , BEIJING, Dec. 1 /PRNewswire-Asia/ ...provider of biopharmaceutical products in China, a...chase order for its H1N1 vaccine, PANFLU.1(TM),fr...chnology for the national,purchase plan. Under thi...n,additional one million doses of PANFLU.1 (TM) (1...
Breaking Medicine Technology:CryoLife Provides Initial 2010 Financial Guidance 2CryoLife Provides Initial 2010 Financial Guidance 3CryoLife Provides Initial 2010 Financial Guidance 4CryoLife Provides Initial 2010 Financial Guidance 5Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 1Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 2Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 3Radiation From Medical Scans Soaring 60144 1Radiation From Medical Scans Soaring 60144 2Radiation From Medical Scans Soaring 60144 3Relevant Security and bitRail Debut RevSecure Product Line 60142 1Relevant Security and bitRail Debut RevSecure Product Line 60142 2Relevant Security and bitRail Debut RevSecure Product Line 60142 3Relevant Security and bitRail Debut RevSecure Product Line 60142 4
(Date:12/1/2009)...ould identify those who would benefit from liver s...ESDAY, Dec. 1 (HealthDay News) -- A CT scan of liv...r may help predict overall survival after chemothe...(Avastin) to cytotoxic chemotherapy has been shown...olorectal cancer and to produce better results in ...
(Date:12/1/2009)... Practitioners of any medi...nscription are breathing a sigh of relief this wee...Phone. The application, released over the holiday...anscribe voice recordings to do so quickly and sea... (PRWEB) December 1, 2009 -- The ...
(Date:12/1/2009)..., , ,, NEW YORK, Dec. 1 /P...and a global leader in the development and deliver...for the medical, scientific and academic markets, ...versal Search, our first-to-market cross-platform ...sychology lexicon, based on the American Psycholog...
(Date:12/1/2009)..., , FORT LAUDERDALE, Fla., Dec. 1 /PRNews... of patient enrollment in the randomized clinical ...g Stent (Combo Stent). ,, A prospective, random... E valuation of an ablu M inal sirolimus coat ... patients at up to 20 sites in Asia, Australia, Eu...
(Date:12/1/2009)... Montreal, December 1, 2009 A Universit de Montra...arch Center on Family Violence and Violence Agains...ffects of pornography on men. "We started our rese...onsumed pornography. We couldn,t find any," says S...professor at the School of Social Work. , "The ...
Breaking Medicine News(10 mins):Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Are the effects of pornography negligible? 2
...C., Oct. 30 It,s no secret that,companies rely he... top,talent. But best-in-class organizations have ... hiring opportunities, according to research from,...izations and, ultimately, into their,work forces. ...
..., Oct. 30 West Anaheim Medical,Center, an affilia...nstalled a state-of-the-art patient tracking and i...ent. Housed within the hospital,s MEDITECH,system,... and efficiently. This patient safety process take...
...A) Specifically aimed, stereotactic radiation may ...ter in treating benign but potentially devastatin...cording to a study by rradiation oncologists at th...ent is effective and the only way to remove the t...
...erts from the U.S Centers for Disease Control, Uni...: HIV Symposium at Association for Molecular Patho...Nov. 7, 9:00 to 10:00 am , Where: Hyatt Regency ... been concerned about HIVs ability to mutate and c...
... and analysis reveal how salaries measure up acros...LADELPHIA, Oct. 30 Case in Point Magazine announc...and Trends Survey.,Presenting professional demogra...prevailing trends. Anne Llewellyn,RN-BC, MS, BHSA,...
... Oct 30 Perrigo Company,(Nasdaq: PRGO ; TASE) to... a,quarterly dividend of $0.05 per share, payable ...November 23, 2007. The new quarterly dividend of,$...care supplier that develops,manufactures and distr...
Other Medicine News:Health News:Lessons Learned in Securing Top Talent During University Recruiting 2Health News:Hospital Launches State-of-the-Art Patient Tracking and Integrated Patient Data System 2Health News:Jefferson oncologists show focused radiation is effective as surgery against nerve tumor 2Health News:Case in Point Magazine Releases 2007 Case Management Salary and Trends Survey 2
Aspartate Aminotransferase (AST) (GOT) IFCC WITH P5P
LDL-Cholesterol (Liquid)
Lipid Control Level 3
Lipid Control Level 2
Medicine Products: